ImmuCell Corporation
ICCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $42,060 | $39,190 | $47,245 | $60,739 |
| - Cash | $3,758 | $979 | $5,792 | $10,185 |
| + Debt | $15,100 | $16,691 | $12,480 | $10,274 |
| Enterprise Value | $53,402 | $54,902 | $53,933 | $60,828 |
| Revenue | $26,493 | $17,472 | $18,568 | $19,243 |
| % Growth | 51.6% | -5.9% | -3.5% | – |
| Gross Profit | $7,941 | $4,396 | $7,649 | $8,656 |
| % Margin | 30% | 25.2% | 41.2% | 45% |
| EBITDA | $1,067 | -$2,504 | $350 | $2,699 |
| % Margin | 4% | -14.3% | 1.9% | 14% |
| Net Income | -$2,157 | -$5,775 | -$2,494 | -$78 |
| % Margin | -8.1% | -33.1% | -13.4% | -0.4% |
| EPS Diluted | -0.26 | -0.75 | -0.32 | -0.01 |
| % Growth | 65.3% | -134.4% | -3,006.8% | – |
| Operating Cash Flow | $358 | -$4,674 | -$1,544 | $954 |
| Capital Expenditures | -$466 | -$1,893 | -$3,975 | -$2,609 |
| Free Cash Flow | -$108 | -$6,567 | -$5,519 | -$1,654 |